Results 171 to 180 of about 1,936,563 (245)

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta   +2 more
wiley   +1 more source

Myelin Impairment and Regeneration in the Central Nervous System: Molecular Mechanisms, Diseases, and Prospective Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Proper myelin formation is crucial for normal neural circuit function, while myelin deficiency can lead to neural circuit dysfunction and cognitive decline, notably in Alzheimer's disease and other central nervous system demyelinating disorders. This review summarizes central myelin's structure and function, demyelination biomarkers and pathological ...
Lihong Huang   +5 more
wiley   +1 more source

Concurrent CML and MBL in a COPD patient: a case of collision hematologic malignancies and opportunistic infection. [PDF]

open access: yesFront Med (Lausanne)
Zhang L   +8 more
europepmc   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao   +7 more
wiley   +1 more source

Vitreoretinal lymphoma revealing Richter transformation. [PDF]

open access: yesAm J Ophthalmol Case Rep
Prabha D, Raval V, Mishra D.
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

open access: yesMedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

open access: yesMedComm, Volume 7, Issue 10, October 2026.
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai   +6 more
wiley   +1 more source

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies. [PDF]

open access: yesNPJ Precis Oncol
Cederlund A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy